On Wednesday we highlighted some small-cap names in biotech and biopharma that should have solid performances in 2018. I believe the year should a good one for the industry, provided tax reform passesAfter being dormant for over a year, I also expect merger-and-acquisition (M&A) activity across the industry to come roaring back in the New YearLarg...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.